In a complaint filed Thurday along with the settlement agreement, Attorney General Catherine Cortez Masto alleged that GSK and SB Pharmco engaged in unfair and deceptive practices when they manufactured and distributed certain lots of Kytril (a sterile drug used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy), Bactroban (an antibiotic ointment used to treat skin infections), Paxil CR (the controlled-release formulation of the popular antidepressant drug Paxil) and Avandamet (a combination Type 2 diabetes drug) that were adulterated because the manufacturing processes used to produce these lots were substandard.
“My fellow attorneys general and I are working to ensure that consumers are protected from deceptive trade practices,” Masto said in a press release. “People rely on the pharmaceutical industry to keep them well and should not have to worry about substandard manufacturing processes.”
GSK and SB Pharmco are no longer manufacturing drugs at their Cidra facility, which has been closed since 2009. As a result of the settlement, GSK and SB Pharmco are enjoined from making false, misleading or deceptive claims regarding the manufacturing of all drugs formerly manufactured at the Cidra facility regardless of where these drugs are now produced. In addition, the companies must not misrepresent those drugs’ characteristics, or cause likelihood of confusion or misunderstanding about the way in which they are manufactured.
Consumers should note that there is no current cause for concern regarding the drugs covered by this agreement because all adulterated batches have been recalled for many years and/or the product’s expiration date has passed. If consumers do have concerns they should contact their health care provider.
Nevada will receive $688,192 in payment from